CardiovascularInvestigational

Angiotensin (1-7)

Subcutaneous injection, Intravenous, Oral

Overview

Angiotensin (1-7) is a seven-amino acid peptide component of the renin-angiotensin system formed through cleavage of angiotensin II by ACE2 or from angiotensin I by endopeptidases. It binds to the Mas receptor to produce vasodilation, anti-proliferative, anti-fibrotic, and anti-inflammatory effects that generally oppose the actions of angiotensin II.

Mechanism of Action

This counter-regulatory arm of the renin-angiotensin system represents a therapeutic target in hypertension, heart failure, and renal disease..

Research Summary & Key Findings

Preclinical studies have demonstrated that angiotensin (1-7) reduces blood pressure, attenuates cardiac remodeling, and improves endothelial function in animal models of cardiovascular disease. Clinical development has been limited by the peptide's short half-life, though modified analogues and oral formulations are under investigation without published phase 3 trial results.

Clinical Status

Investigational

Angiotensin (1-7) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injectionIntravenousOral

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Angiotensin (1-7) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Angiotensin (1-7).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.